Floatz logo

229 assets in Metastatic Prostate Carcinoma

Therapeutic assets addressing Metastatic Prostate Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
AXUMIN
Metastatic Prostate Carcinoma
VA Greater Los Angeles Healthcare SystemP4BBB (73)
Leuporelin
Metastatic Prostate Carcinoma
Mayo ClinicP4BBB (72)
Abiraterone
Metastatic Prostate Carcinoma
Mayo ClinicP4BB (70)
Prednisone
Metastatic Prostate Carcinoma
Mayo ClinicP4BB (70)
Pembrolizumab
Metastatic Prostate Carcinoma
CuraCell TX ABP2BB (69)
Cabazitaxel
Metastatic Prostate Carcinoma
AstraZenecaP4BB (68)
Carboplatin
Metastatic Prostate Carcinoma
Case Comprehensive Cancer CenterP3BB (68)
Degarelix
Metastatic Prostate Carcinoma
Praful Ravi, MB BCHir, MRCPP3BB (68)
Sipuleucel-T
Metastatic Prostate Carcinoma
Yale UniversityP2BB (68)
Apalutamide
Metastatic Prostate Carcinoma
AstraZenecaP4BB (67)
Enzalutamide
Metastatic Prostate Carcinoma
AstraZenecaP4BB (67)
Piflufolastat
Metastatic Prostate Carcinoma
Brigham and Women's HospitalP4BB (67)
Prednisolone
Metastatic Prostate Carcinoma
BioNTech SEP4BB (67)
Bicalutamide
Metastatic Prostate Carcinoma
Washington University School of MedicineP4BB (66)
Goserelin
Metastatic Prostate Carcinoma
The First Affiliated Hospital of Xiamen UniversityP4BB (66)
Saruparib
Metastatic Prostate Carcinoma
AstraZenecaP3BB (66)
Cediranib
Metastatic Prostate Carcinoma
National Cancer Institute (NCI)P2BB (65)
Ipilimumab
Metastatic Prostate Carcinoma
Andrew J. Armstrong, MDP2BB (65)
Olaparib
Metastatic Prostate Carcinoma
Fusion Pharmaceuticals Inc.P4BB (65)
Docetaxel
Metastatic Prostate Carcinoma
Georgetown UniversityP3BB (64)
Radium Ra-223
Metastatic Prostate Carcinoma
AstraZenecaP4BB (64)
Relugolix
Metastatic Prostate Carcinoma
University of UtahP3BB (64)
Darolutamide
Metastatic Prostate Carcinoma
West China HospitalP3B (63)
Dexasone
Metastatic Prostate Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsP4B (63)
Flotufolastat F 18
Metastatic Prostate Carcinoma
Washington University School of MedicineP4B (63)
Cyclophosphamide
Metastatic Prostate Carcinoma
Beijing BiotechP3B (62)
Vipivotide Tetraxetan
Metastatic Prostate Carcinoma
Mayo ClinicP3B (62)
NORVIR
Metastatic Prostate Carcinoma
University of ChicagoP2B (61)
Atezolizumab
Metastatic Prostate Carcinoma
Dana-Farber Cancer InstituteP3B (60)
Capivasertib
Metastatic Prostate Carcinoma
Karolinska InstitutetP3B (60)
Cis-Diamminedichloroplatinum Ii
Metastatic Prostate Carcinoma
The First Affiliated Hospital of Xiamen UniversityP3B (60)
Durvalumab
Metastatic Prostate Carcinoma
Rahul AggarwalP2B (60)
Ipatasertib
Metastatic Prostate Carcinoma
Institute of Cancer Research, United KingdomP3B (60)
Mevrometostat
Metastatic Prostate Carcinoma
PfizerP3B (60)
Niclosamide
Metastatic Prostate Carcinoma
University of California, DavisP2B (60)
Opevesostat
Metastatic Prostate Carcinoma
Merck Sharp & Dohme LLCP3B (60)
Psma I&T
Metastatic Prostate Carcinoma
CHU de Quebec-Universite LavalP3B (60)
SX682
Metastatic Prostate Carcinoma
Institute of Cancer Research, United KingdomP2B (60)
Talazoparib
Metastatic Prostate Carcinoma
Fundacion OncosurP2B (60)
Abemaciclib
Metastatic Prostate Carcinoma
Praful Ravi, MB BCHir, MRCPP2B (59)
Bet Bromodomain Inhibitor Zen-3694
Metastatic Prostate Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsP2B (59)
Fludeoxyglucose
Metastatic Prostate Carcinoma
University of Wisconsin, MadisonP2B (59)
Niraparib
Metastatic Prostate Carcinoma
Qian QinP3B (59)
Cabozantinib
Metastatic Prostate Carcinoma
University of UtahP3B (58)
Nivolumab
Metastatic Prostate Carcinoma
Parabilis Medicines, Inc.P2B (58)
Bavdegalutamide
Metastatic Prostate Carcinoma
Arvinas Androgen Receptor, Inc.P1/2B (57)
Dasatinib
Metastatic Prostate Carcinoma
St Vincent's Hospital, SydneyP2B (57)
Sar-Bispsma, Cu-64
Metastatic Prostate Carcinoma
Curium US LLCP2B (57)
azd2265
Metastatic Prostate Carcinoma
AstraZenecaP3B (56)
Etoposide
Metastatic Prostate Carcinoma
Fudan UniversityP2B (56)
Showing 1 to 50 of 229 assets
PreviousPage 1 of 5Next